[ad_1]
Medications commonly prescribed to treat prostate problems have been badociated with an increased risk of type 2 diabetes in men who take them. The study joins earlier research that showed that these drugs could decrease insulin sensitivity in patients, a harbinger of the possible development of type 2 diabetes. However, the team at the The latest research warns that patients should not stop taking their medications. Instead, the data reveals that patients need to ensure that they are correctly screened.
The prostate medications work by reducing the patient's androgen levels, resulting in shrinkage of the prostate and improving symptoms. This is good for patients with related conditions, but bad news if this translates into the development of type 2 diabetes, which is itself a serious disease.
Patients should not stop taking their medication, the researchers warn. Knowing the potential risk of type 2 diabetes badociated with these medications allows health professionals to monitor these patients. Identifying the presence of warning signs allows patients to make changes to their lifestyle and, if necessary, to obtain the necessary medications to cope with the problem.
The conclusion is based on a study of the medical records of 55,000 British men who had been prescribed a 5-alpha-reductase inhibitor. The risk of developing type 2 diabetes had increased by about one-third in these men. Ruth Andrew, principal professor and author of the study, spoke about the research:
We found that drugs commonly prescribed for the treatment of prostate disease may increase the risk of type 2 diabetes. These findings will be particularly important for medical screening in older men who are already at higher risk of developing diabetes. type 2. We will now continue our studies to better understand the long-term results in order to better identify the most exposed patients.
Source link
